Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $501.00. The company’s shares ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
LONDON, January 31, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 ...
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period. There have been no specific sales or ...
The official kits for all eight teams in the ICC Champions Trophy 2025 have been unveiled, featuring bold new designs and vibrant colours. See how each nation will represent themselves on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback